However, patients with biliary tract cancers with IHC 2+/ISH+ did not have meaningful treatment responses to T-DXd while patients with HER2 IHC 2+/ISH+ gynecologic cancers had high response rates (34). Here, ERBB2 is linked to biliary tract cancer.